Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort

Konopnicki, Déborah; Mocroft, Amanda; Wit, Stéphane De; Antúnes, Francisco; Ledergerber, Bruno; Katlama, Christine; Zilmer, Kai; Vella, Stefano; Kirk, Ole; Lundgren, Jens D

doi:10.1097/01.aids.0000163936.99401.fe

Cited by 506 publications

(471 citation statements)

References 25 publications

Supporting

Mentioning

404

Contrasting

Unclassified

Order By: Relevance

“…Liver disease is one of the major causes of morbidity and mortality in HIV-infected patients [75,76], and its severity has been associated with more advanced immunosuppression. HCV/HIV co-infection may accelerate HIV-related neurocognitive decline [69].…”

Section: Co-infection With Hepatic Virusesmentioning

confidence: 99%

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Co-infection With Hepatic Virusesmentioning

confidence: 99%

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…HIV-positive persons Konopnicki et al [66] Cohort study (EuroSIDA Cohort, n=9802) from 72 HIV centers, Europe…”

Section: Group Of Persons Study Study Setting Resultsmentioning

confidence: 99%

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Harder

Remschmidt

Falkenhorst

et al. 2013

Bundesgesundheitsbl.

View full text Add to dashboard Cite

“…1 The hepatitis B surface antigen (HBsAg) is over five times more prevalent among HIV-infected patients than in the general population. [2][3][4] In North America and Europe, more than half of HIVinfected men who have sex with men have evidence of past HBV infection, and 5-10% have chronic hepatitis B, which is defined as the persistence of HBsAg in serum for longer than 6 months. 5 C chronic hepatitis B is more likely to develop and persist after HBV in patients with HIV infection.…”

Section: Introductionmentioning

confidence: 99%

“…[2][3][4] In North America and Europe, more than half of HIVinfected men who have sex with men have evidence of past HBV infection, and 5-10% have chronic hepatitis B, which is defined as the persistence of HBsAg in serum for longer than 6 months. 5 C chronic hepatitis B is more likely to develop and persist after HBV in patients with HIV infection. 6,7 Patients with chronic hepatitis B and underlying HIV infection (HIV-HBV co-infection) are also at higher risk of cirrhosis and hepatocellular carcinoma when compared with HBV-mono-infected individuals.…”

Section: Introductionmentioning

confidence: 99%

Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India

Isaakidis¹,

Mansoor²,

Zachariah³

et al. 2012

International Health

View full text Add to dashboard Cite

CitationTreatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus coinfection in Mumbai, India 2012, 4 (4) Treatment experiences with patients co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in resource-limited settings remain poorly documented.This study aimed to evaluate the treatment outcomes in a cohort of HIV/HBV co-infected individuals receiving tenofovir/lamivudine (TDF/3TC)-based antiretroviral therapy (ART) in a programmatic setting in Mumbai, India. Additionally, a cross-sectional laboratory study was carried out measuring serologic and virologic parameters. A total of 57 patients who received TDF/3TC were included in the study. Of these, 52 (91%) were male and the mean age was 38.7 years. The median follow-up period was 16.8 months (IQR:7.9-37.9). Forty-three patients were included in the cross-sectional laboratory study, of whom 38 (67%) were HBeAg + positive. Four patients had serum HBsAg conversion to negative and had developed anti-HBs-antibodies. HBV-DNA became undetectable (<1.3 log 10 copies/ml or <20 IU/ml) in 35.5% and 75% of the HBeAg + and HBeAg − patients, respectively. Overall, 46.5% of patients had undetectable HBV-DNA and 90.7% had adequately suppressed HBV-DNA (<3.3 log 10 copies/ml or <2000 IU/ml). The median reduction in serum HBV-DNA was 6 log 10 copies/ml. In 29 patients (63%) HIV viral load was undetectable. Outcomes included seven (12%) deaths, four (7%) lost to follow-up, one (2%) transferred out and 45 (79%) alive and on treatment. In conclusion, good treatment outcomes were achieved in a cohort of HIV/HBV co-infected patients in India. In regions with a high HIV/HBV burden, all HIV-infected individuals should be tested for chronic hepatitis B. A TDF/3TC-backbone could be considered as first-line standardized ART regimen in these settings.

show abstract

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort

Abstract: The prevalence of HBV coinfection was 9% in the EuroSIDA cohort. Chronic HBV infection significantly increased liver-related mortality in HIV-1-infected patients but did not impact on progression to AIDS or on viral and immunological responses to HAART.

Cited by 506 publications

References 25 publications

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India

Contact Info

Product

Resources

About